PRTN3 and COVID-19: Comparing the prevalence of RF and ACPA in a sample of 33 subjects from a Colombian post-COVID-19 clinic, Acosta-Ampudia et al. noticed that the autoantibody positivity did not change from acute disease to post-COVID-19 assessment at a median time of 266 days and that the frequency of these autoantibodies was not different compared with a control group of healthy individuals [25].